Molecular biology of gallbladder cancer: potential clinical implications

• Published in: North American journal of medical sciences 2012-10, Vol.4 (10), p.435-441
• Main Author: Andrén-Sandberg, Ake
• Format: Article
• Language: English
• Subjects: Analysis; Care and treatment; Development and progression; Diagnosis; DNA damage; Gallbladder cancer; Genetic aspects; Medicin och hälsovetenskap; Molecular biology; Review
• ISSN: 1947-2714; 2250-1541; 1947-2714
• DOI: 10.4103/1947-2714.101979

Gallbladder cancer (GBC) is a common malignancy of the biliary tract and involves the changes in multiple oncogenes and multiple genetic genes. Since over the past decade there has been an advance in the knowledge of the genetic basis of cancer, mainly as a result of the rapid progression of molecular technology; however, conventional therapeutic approaches have not had much impact on the course of this aggressive neoplasm. Knowledge of the molecular biology of GBC is rapidly growing. Genetic alterations in GBC include adenosine triphosphate-binding cassette transporter ABCG8, membrane-bound enzyme ADAM-17 of multi-functional gene family, and other genes including p53, COX2, XPC, and RASSF1A. The advances in molecular biology have potential implications for the detection of this disease, using Synuclein-gamma, Syndecan-1, glycoprotein 72 (TAG-72), tumor endothelial marker 8 protein (TEM8) and TNF-alpha. The use of these molecular diagnostic methods is of clinical importance for the gene replacement therapy, genetic prodrug activation therapy, and antisense immunology technology for the treatment of malignancy. The author reviewed recent publications on PubMed, and summarized molecular biology of GBC, with an emphasis on features of potential clinical implications for diagnosis and management.